CA
NZ
UK
AU
IND
US
…
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Athersys, Inc. is a clinical-stage biotechnology company developing regenerative cell therapies based on its MultiStem platform for inflammatory, ischemic and immune-mediated conditions. Long-term growth may be driven by successful trials, regulatory approvals and licensing or commercialization deals that could support wider adoption of its allogeneic MultiStem platform, which may appeal to investors seeking exposure to regenerative medicine.
Key investment risks include failure in clinical development or regulatory review, limited or no commercial revenue, ongoing financing needs and low liquidity associated with its OTC/PINK listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -72.53M | -86.95M | -78.77M | -44.58M |
| Net income | -72.53M | -86.95M | -78.77M | -44.58M |
| Selling general administrative | 15.88M | 20.07M | 15.89M | 11.38M |
| Reconciled depreciation | 1.42M | 1.43M | 0.89M | 0.70M |
| Operating income | -77.01M | -87.06M | -78.33M | -45.49M |
| Total revenue | 5.33M | 5.51M | 1.43M | 5.52M |
| Total operating expenses | 82.33M | 92.57M | 79.76M | 51.01M |
| Total other income expense net | 4.47M | 0.10M | -0.43M | 0.91M |
| Net income from continuing ops | -72.53M | -86.95M | -78.77M | -44.58M |
| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 27.73M | 60.18M | 59.71M | 41.67M |
| Other current assets | 1.03M | 1.34M | 2.93M | 1.19M |
| Total liab | 51.58M | 43.81M | 28.35M | 18.39M |
| Total stockholder equity | -23.85M | 16.37M | 31.36M | 23.27M |
| Other current liab | 0.53M | - | - | - |
| Capital stock | 0.02M | 0.01M | 0.20M | 0.16M |
| Retained earnings | -655.88M | -583.34M | -496.39M | -417.62M |
| Cash | 9.04M | 37.41M | 51.55M | 35.04M |
| Total current liabilities | 38.44M | 29.86M | 22.95M | 12.84M |
| Total current assets | 13.54M | 46.03M | 54.56M | 37.17M |
| Net receivables | 0.72M | 1.41M | 0.09M | 0.94M |
| Accounts payable | 27.77M | 16.90M | 13.04M | 10.12M |
| Non currrent assets other | 2.14M | 1.50M | 1.35M | 1.61M |
| Non current assets total | 14.20M | 14.16M | 5.15M | 4.50M |
| Capital lease obligations | 8.69M | 9.77M | 0.68M | - |
| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -0.26M | -1.36M | -1.16M | -0.58M |
| Total cash from financing activities | 30.84M | 63.41M | 79.48M | 19.89M |
| Net income | -72.53M | -86.95M | -78.77M | -44.58M |
| Change in cash | -28.37M | -14.14M | 16.50M | -16.02M |
| Begin period cash flow | 37.41M | 51.55M | 35.04M | 51.06M |
| End period cash flow | 9.04M | 37.41M | 51.55M | 35.04M |
| Total cash from operating activities | -58.95M | -76.19M | -61.81M | -35.33M |
| Issuance of capital stock | 31.02M | 64.26M | 72.78M | 20.31M |
| Depreciation | 1.42M | 1.43M | 0.89M | 0.70M |
| Change to account receivables | 3.70M | -4.33M | 0.86M | 3.78M |
| Capital expenditures | 0.40M | 1.36M | 1.16M | 0.58M |
| Change in working capital | 2.95M | 0.55M | 8.69M | 3.71M |
| Stock based compensation | 6.20M | 8.56M | 7.38M | 4.85M |
| Other non cash items | - | 0.23M | - | - |
| Free cash flow | -59.35M | -77.55M | -62.97M | -35.91M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634
216 431 9900
24
| Name | Title | Year Born |
|---|---|---|
| Ms. Z. Kasey Rosado | Interim CFO & Director | 1974 |
| Senthil Ranganathan Ph.D. | Vice President of Technical Operations | NA |
| Mr. David Russ M.B.A. | Vice President of Supply Chain, Finance & Administration | NA |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Executive VP & Head of Global Regulatory Affairs | NA |
| Dr. Robert Mays Ph.D. | Executive VP, Head of Regenerative Medicine & Neuroscience Programs | NA |
| Mr. Rakesh Ramachandran MS | Head of Information Technology & Communications and VP | NA |
| Dr. Sarah Busch Ph.D. | VP of Regenerative Medicine & Head of Business Development | NA |
| Ms. Ellen Gurley | Manager of Corporate Communications and Investor Relations | NA |
| Dr. Senthil Ranganathan Ph.D. | Vice President of Technical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...